Gurujoe
Oct 2, 2:16 PM
$GLUE — I think the market is dramatically underappreciating what MRT-8102 just showed.
This wasn’t simply “CRP went down.”
After only 4 weeks of oral therapy, MRT-8102 produced ~80–90% NEK7 degradation and hit an extraordinary number of inflammatory, atherogenic and thrombogenic biomarkers:
• hsCRP ↓85%
• IL-6 ↓54%
• Calprotectin ↓56%
• S100A12 ↓46%
• SAA ↓51%
• Fibrinogen ↓28%
• Lp(a) ↓24%
• HMGB1 ↓40% in high-baseline subjects
• IL-1β ↓37% in high-baseline subjects
Several biomarkers moved toward levels seen in healthy volunteers.
Now consider the human validation.
CANTOS previously demonstrated that IL-1β inhibition could reduce CV events. Low-dose colchicine—which indirectly affects NLRP3/inflammation—is already FDA approved for reducing cardiovascular events.
Meanwhile Novo’s ziltivekimab produced major IL-6/CRP suppression but recently FAILED Phase 3 ZEUS on MACE (HR 0.99) and had more serious infections.
That’s precisely why MRT-8102 is fascinating.
Rather than blocking ONE downstream cytokine,
$GLUE is degrading NEK7 upstream of NLRP3, potentially suppressing multiple pathogenic outputs simultaneously.
And so far:
No SAEs.
No observed increased infection risk.
TEAEs 33% vs 30% placebo.
Oral small molecule.
Obviously 4-week Phase 1 biomarker data ≠ clinical efficacy. Phase 2 must prove this translates into plaque modification and ultimately outcomes.
But the commercial opportunity if it does is enormous.
ASCVD: ~18.7M U.S. patients; ~60% reportedly have CRP >2 mg/L → roughly 11M residual-inflammatory-risk patients.
Even a hypothetical
$5,000/year × 5% penetration of that population = ~
$2.8B annual U.S. revenue opportunity.
And ASCVD isn’t the entire MRT-8102 opportunity:
GOUT: 9.2M U.S. adults.
At
$5K/year × only 5% penetration = **
$2.3B theoretical annual revenue.**
HIDRADENITIS SUPPURATIVA: estimates approaching ~2.9M U.S. patients, with the U.S. treatment market projected around
$5.4B by 2034.
Approved HS biologics include Humira, Cosentyx and Bimzelx, while Merck just reported strong Phase 2 tulisokibart data.
MRT-8102 could potentially bring something very different:
oral + upstream + multi-biomarker suppression + encouraging early safety.
ASCVD + gout + HS creates a potential multi-billion-dollar franchise if Phase 2 converts this extraordinary pharmacology into clinical efficacy.
The biggest question is no longer whether MRT-8102 engages NEK7/NLRP3.
It clearly does.
The multibillion-dollar question is whether this remarkably broad biological response translates into disease modification.
GFORCE-2 may be one of the most important Phase 2 studies in the
$GLUE pipeline.
For research/discussion only. Revenue examples are illustrative assumptions, not forecasts.
0 replies
